Boardroom Alpha
Meeting calendar
AXGN · Annual meeting · Tuesday, June 23, 2026

Axogen Inc

8 nominees · 3 ballot items.

Elect eight directors; ratify Deloitte & Touche LLP as independent auditors; advisory (non-binding) approval of named executive officer compensation.

Market cap
$2.1B
1Y TSR
+255.8%
Board grade
B
Record date
Apr 24, 2026
Filing
DEF 14A
Meeting concluded · Jun 23, 2026

Follow how the vote landed and what changed on Axogen Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.

Proposals

On the ballot3

  1. 1

    Election of Directors

    ManagementBoard: FOR

    Elect eight directors—Paul Thomas, Michael Dale, William Burke, John H. Johnson, Alan M. Levine, Joseph Tyndall, Kathy Weiler and Amy Wendell—to hold office for one year.

  2. 2

    Ratification of Appointment of Independent Registered Public Accounting Firm

    ManagementBoard: FOR

    Ratify Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026.

    More detail

    This management proposal asks shareholders to ratify the Audit Committee’s selection of Deloitte & Touche LLP as the company’s independent registered public accounting firm for fiscal 2026. Management seeks shareholder ratification as a governance best practice and to provide an affirmative shareholder endorsement for the continued engagement; the Audit Committee has oversight of auditor selection and has pre-approved fees and services, and Deloitte has served since March 2018. This is a routine proposal (auditor ratification) and is typically non-controversial; the board recommends a vote FOR because maintaining the incumbent auditor supports continuity, and the Audit Committee concluded that Deloitte’s services during prior years were compatible with independence. Because this is a routine auditor ratification, no extended analyst-level evaluation is required.

  3. 3

    Non-Binding Advisory Vote on Named Executive Officer Compensation

    ManagementBoard: FOR

    Advisory approval (say-on-pay) of the compensation of the Company’s named executive officers as disclosed in the proxy statement.

    More detail

    This management proposal is an advisory (non-binding) 'say-on-pay' vote asking shareholders to approve the disclosed compensation of the company’s named executive officers. Management requests this advisory approval to confirm shareholder support for executive pay policies and practices described in the CD&A, which emphasize performance-based incentives, PSUs tied to revenue CAGR and TSR, RSUs for retention, clawback policies and pay governance. The Board recommends a vote FOR, citing alignment of compensation with long-term shareholder value and prior shareholder support (~90% in 2025). As an advisory measure, the result will be considered by the Compensation Committee when assessing future compensation arrangements but will not directly change pay without further board action.

Director elections

Nominees on the ballot8

Independent
Tenure on this board
5.8 yrs
Also a director at
Tela Bio Inc (TELA)
Not independent
Tenure on this board
1.9 yrs
Also a director at
Cvrx Inc (CVRX)
Independent
Tenure on this board
5.0 yrs
Also a director at
Xeris Biopharma Holdings Inc (XERS)
Independent
Tenure on this board
9.8 yrs
Also a director at
Baxter International Inc (BAX)Solventum Corp (SOLV)
Ownership

Top institutional holders10

Latest 13F quarter
1First Light Asset Management, LLC7.5%4,002,768$133M
2VANGUARD CAPITAL MANAGEMENT LLC4.3%2,291,563$76M
3MORGAN STANLEY4.2%2,209,528$73M
4BlackRock, Inc.3.8%2,024,522$67M
5ArrowMark Colorado Holdings LLC3.6%1,915,439$63M
6WASATCH ADVISORS LP3.5%1,857,350$62M
7Polar Capital Holdings Plc2.8%1,500,822$50M
8BlackRock, Inc.2.6%1,390,944$46M
9Assenagon Asset Management S.A.2.6%1,381,263$46M
10FMR LLC2.3%1,205,955$40M
Filings

Recent key filings

Periodic reports
Definitive proxies
Reference

Frequently asked questions

When is the Axogen Inc 2026 annual meeting?
Axogen Inc (AXGN) holds its 2026 annual shareholder meeting on Tuesday, June 23, 2026.
What is the record date for the Axogen Inc 2026 meeting?
The record date for the Axogen Inc 2026 meeting is Friday, April 24, 2026. Shareholders of record on or before that date are eligible to vote.
Who are the director nominees for Axogen Inc's 2026 meeting?
The board is presenting 8 director nominees at the Axogen Inc 2026 meeting, listed with their independence status and background.
What proposals will shareholders vote on at the Axogen Inc 2026 meeting?
Shareholders will vote on 3 proposals at the Axogen Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer